[Alpha-glucosidase inhibitor and insulin sensitizer combination therapy in NIDDM].
Kitaoka
H
H
First Department of Internal Medicine, Osaka Medical College.
D020909:Acarbose; D000818:Animals; D002839:Chromans / Q000008:administration & dosage*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007294:Inositol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D007333:Insulin Resistance; D000077205:Pioglitazone; D013844:Thiazoles / Q000008:administration & dosage*; D045162:Thiazolidinediones; D014312:Trisaccharides / Q000008:administration & dosage*; D000077288:Troglitazone
D002839:Chromans; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D014312:Trisaccharides; D007294:Inositol; D000077288:Troglitazone; C102817:voglibose; D020909:Acarbose; D000077205:Pioglitazone